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Abstract 
The major symptom of Alzheimer’s disease is rapidly progressing dementia, coinciding with 
the formation of amyloid and tau deposits in the central nervous system, and neuronal death. 
At present familial cases of dementias provide the most promising foundation for modelling 
neurodegeneration. We describe the mnemonic and other major behavioral symptoms of 
tauopathies, briefly outline the genetics underlying familiar cases and discuss the arising 
implications for modelling the disease in mostly transgenic mouse lines. We then depict to 
what degree the most recent mouse models replicate pathological and cognitive 
characteristics observed in patients. There is no universally valid behavioral test battery to 
evaluate mouse models. The selection of individual tests depends on the behavioral and/or 
memory system in focus, the type of a model and how well it replicates the pathology of a 
disease and the amount of control over the genetic background of the mouse model. 
However it is possible to provide guidelines and criteria for modelling the neurodegeneration, 
setting up the experiments and choosing relevant tests. One should not adopt a ―one 
(trans)gene, one disease‖ interpretation, but should try to understand how the mouse 
genome copes with the protein expression of the transgene in question. Further, it is not 
possible to recommend some mouse models over others since each model is valuable within 
its own constraints, and the way experiments are performed often reflects the idiosyncratic 
reality of specific laboratories. Our purpose is to improve bridging molecular and behavioural 
approaches in translational research. 
 
Key words: Tauopathy, Alzheimer’s disease, transgenic models, phenotype, behavioural 
tests. 
 
Abbreviations: 
AD Alzheimer’s disease 
A_ _-amyloid peptide 
FAD amilial Alzheimer’s disease 
FTD fronto-temporal dementia 
FTDP-17 fronto-temporal dementia with parkinsonism linked to chromosome 17 
GLM general linear model 
MAPT microtubule-associated protein Tau 
MCI mild cognitive impairment 
NFT neurofibrillary tangles 
 
1. Introduction 
One hundred years ago Alois Alzheimer described in a seminal 
paper the behavioural symptoms of his patient, Auguste D., 
who suffered from a mental illness (2), (see (3) for English translation 
of the original paper). He observed that ―[S]he developed 
a rapid loss of memory. She was disoriented in her home, 
[. . .] She is completely disoriented in time and space. Her memory 
is seriously impaired. If objects are shown to her, she names 
them correctly, but almost immediately afterwards she has forgotten 
everything.‖ After the patient died, an autopsy revealed 
dense deposits outside and around nerve cells and twisted 
strands of fibre inside dead neurons in her brain. Today these 
two pathological hallmarks of Alzheimer’s disease (AD) are 
known to be extra-cellular plaques made largely of _-amyloid 
peptide (A_) and intracellular neurofibrillary tangles composed 
of hyper-phosphorylated microtubule-associated protein tau 
(4, 5). 
The current view is that almost all neurodegenerative disorders 
can be broadly classified as disorders of protein folding 
(6). The accumulation of misfolded proteins may be, as 
in the case of AD, intra- and extra-cellular, or only intracellular, 
with abnormally phosphorylated protein tau aggregates 
being most common. The most common is tau protein 
which aggregates within neurons in hyper-phosphorylated 
form (7, 8) and causes profound loss of neurons and atrophy 
of the brain (9–11). Neurodegenerative diseases characterised 
by the presence of hyper-phosphorylated tau are collectively 
termed tauopathies (7, 12). The degeneration of neurons 
in tauopathies leads to dementia, i.e., a progressive and 
accelerating decline in mental function. AD is one of the most 
devastating tauopathies in which a patient’s memory and ability 
to learn is initially compromised and eventually completely 
destroyed. Although the behavioural pathologies of tauopathies 
resemble each other, there is also much variation in the clinical 
picture due to specific combination of neuropathological changes, 
variations in the form of hyper-phosphorylated tau and the 
individual spatio-temporal expression of neurodegeneration 
(reviewed by 7). 
 
2. Tauopathy - Hallmarks and Characteristics 
 
2.1. Compromised Behaviour 
Tauopathies are diseases characterised by a progressive and severe 
decline in cognitive abilities that cannot be attributed to normal 
aging (13). Abnormalities in other behavioural systems often 
precede and accompany tauopathies (14). In AD, signs of mild 
cognitive impairment (MCI) precede overt dementia (15). In 
practice, individuals will only be classified as cognitively impaired 
when their ability to perform everyday tasks is compromised to 
the point that they are no longer able to function at home and in 
their community (16). MCI diagnostic does not always correctly 
predict the development of AD-type dementia. Data derived from 
neuroimaging, screening for genetic risk factors (17) or detection 
of increased tau protein levels in cerebrospinal fluid (18, 
19) might provide false-positive indications of beginning dementia. 
Even significant hippocampal atrophy is not always a reliable 
marker and might be due to depression, Parkinson’s disease, or 
vascular dementia (17). Diagnosis of AD is also complicated since 
amyloid plaques and neurofibrillary tangles (NFTs) of hyperphosphorylated 
tau are present during normal aging. Further, depending on the type of  
tauopathy, patients may present a variety of other cognitive complaints  
including delusions, amnesia, executive dysfunction, apathy, agitation,  
and aggressive behaviour (8, 19–22). 
 
2.2. Neuropathology  
Tauopathies are characterised by neuronal dysfunction and loss 
that display a varying but overlapping spatio-temporal distribution 
(reviewed in 8). The neuropathological variability is the reason 
for the complex and also varying clinical phenotypes. In AD, 
progressive neuronal damage and death appear in brain regions 
critical for learning and memory (neocortex, hippocampus, amygdala, 
anterior thalamus, basal forebrain, and subcortical nuclei 
including the nucleus basalis of Meynert (23–28)). The highest 
atrophy is seen in the entorhinal cortex and hippocampus (29) 
which positively correlates with the degree of dementia (30). The 
development of neuropathology is paralleled by a decreased functionality 
of forebrain and brainstem monoaminergic and cholinergic 
systems (4, 31–33). 
 
2.3. Intra- and Extra-cellular Protein Inclusions 
The main characteristic of tauopathies is an age-progressing 
hyper-phosphorylation of the tau protein which accumulates in 
tangles with paired helical filaments, twisted ribbons, and/or 
straight filaments (7, 34). Excessive intra-neuronal deposition of 
tau protein is also a key feature of dying neurons during normal 
aging (35, 36). Kidd, studying brains of AD patients, was 
the first to show that both tangles and neuritic plaques contain 
dense accumulation of pathological paired helical filaments 
(37). In the mid-1980s, tau was identified to be the principal 
component of neurofibrillary lesions in the AD (34, 38, 39). 
Similar lesions were also found in other neurodegenerative diseases 
including corticobasal degeneration (40), amyotrophic lateral 
sclerosis/parkinsonism dementia complex of Guam (41, 42), 
Down syndrome (43), progressive supranuclear palsy, Pick’s disease, 
argyrophilic degeneration (reviewed by 7), myotonic dystrophy 
(44), and the family of fronto-temporal dementias (FTD) 
(45). AD is a special form of tauopathy additionally characterised 
by extra-cellular deposits of A_ and amyloid deposits in cerebral 
blood vessels (46). Plaques consist mainly of a 40–42 residue 
_ amyloid peptide (A_40/A_42), cleaved from the amyloid precursor 
protein (APP) and are surrounded by dystrophic nerve 
cells. The longer A_42 species is normally present in small, soluble 
fractions in biological fluids (47), but it is elevated and early 
deposited in cases of familial Alzheimer’s disease (FAD) (48, 49). 
The increase in levels of both A_40 and A_42 correlates with 
progress in cognitive decline (50), and the increase in A_40 peptide 
was detected in 40% of AD patients before overt amyloid 
plaques could be detected. Moreover, the increase in A_ preceded 
the formation of NFT, suggesting that at least in the frontal cortex 
of some cases, soluble species of A_ may precipitate the formation 
of NFTs. However, since tau pathology can occur in the 
absence of A_ other causes of NFT formation cannot be excluded 
(50). 
 
2.4. Genetics  
The first gene mutations related to familial neurodegeneration 
were identified in AD in the gene encoding amyloid b precursor 
protein (APP) (51–53), followed by mutations in presenilin 1 
(PSEN1) (54, 55) and presenilin 2 (PSEN2) (56, 57). No mutations 
directly associated with NFTs have been identified in AD. 
However, several groups of patients with FTD inherited autosomal 
dominant mutations in MAPT in FTDP-17 were reported 
(58–60). Approximately 100 families with FTDP-17 have now 
been identified, with a total of 32 unique tau gene mutations (61, 
62). Moreover, in addition to MAPT, mutations in progranulin, 
which encodes a growth factor involved in the regulation of multiple 
processes including development, wound repair, and inflammation, 
were recently shown to be implicated in FTDP-17 (63). 
Finally, mutations in PSEN1 gene, implicated in AD, can produce 
FTD-like phenotypes with the AD neuropathology (reviewed 
by 64). 
 
2.5. Conclusions  
The identification of gene mutations implicated in tauopathies 
opened a way to model the diseases in mice. At translational 
research level, the work is focusing on the production of experimental 
animal models that reproduce the essential pathology 
and phenotype of human tauopathies, including the formation 
of abundant, specific to a disease intra- and/or extra-cellular protein 
inclusions, neuronal degeneration, and cognitive impairment. 
Therefore such animal models should have the following characteristics: 
(1) specific to a given disorder, intra- and/or extracellular 
deposition of misfolded proteins, (2) age-progressing 
dementia, (3) disturbance in behavioural systems not related 
directly to cognitive function but which are observed at specific 
stages of a disease, and (4) coinciding neuronal loss in diseasespecific 
brain regions and cytoarchitecture. 
 
3. Mouse Models of Neurodegeneration 
The first successful mouse model replicating major hallmarks of 
neurodegenerative disease was an AD mouse model created more 
than a decade ago by Games and colleagues (65). Other AD 
mouse models followed soon and were proven extremely informative, 
which was chronicled in number of scholarly reviews 
(66–77). Mouse models expressing genes implicated in other 
tauopathies followed closely (reviewed by 7, 70, 78, 79). 
 
3.1. Criteria of Mouse Models of Tauopathies 
At the juncture of over a decade long history of using mouse 
models of neurodegeneration, it seems that a robust and good 
model should meet the following guidelines: 
 
1. Replication of clinical phenotypes. 
Since the cognitive decline and region-specific neuronal loss 
are central to neurodegenerative diseases, the model of a disease 
should recapitulate accurately these facets of the clinical 
phenotype. 
 
2. Age-progressing phenotype. 
A credible model should exhibit age-progressive neuropathology 
and cognitive deficits which could be evident, 
to various extent, in paradigms addressing different memory 
systems. The extent of age-progressing behavioural impairment 
may eventually encompass non-cognitive systems due 
to a significantly increasing brain pathology. Although, this 
may raise operational complexities associated with the interpretation 
of the cognitive impairment being confounded by 
the emergence of impairment in non-cognitive behavioural 
systems (80), the use of such model during drugs screens 
may reveal which behavioural deficiencies can be ameliorated 
by a treatment at given stage of pathology. 
 
3. Control for the effect of genetic mutation. 
In the models employing genetic mutations (transgenic 
models), phenotyping changes should be robust and correlated 
with the presence of familial mutations, but should be 
absent or less overt in the age-matched mice expressing wildtype 
(wt, non-mutated) gene expressed at equal (or greater) 
steady-state levels. These mouse models require minimum 
variation in their genetic background in order to be sensitive 
to pick up subtle changes in a phenotype. Therefore, whenever 
possible inbred strains, having homozygous genomes, 
are used almost exclusively in biomedical research. Transgenic 
lines, however, are often created in one strain and later 
backcrossed to more suitable genetic background, which 
complicates the control over genetic variability.Wild-derived 
mouse strains or recombinant strains are usually avoided in 
transgenic research due to unwanted genetic diversity. Similarly, 
outbred stocks, used predominantly in genetics, toxicology, 
and pharmacology, are not recommended for transgenic 
research due to their genetic variability caused by 
genetic drift, directional selection, and genetic contamination 
during breeding (81–83). 
 
4. Validation of a model. 
The independent confirmation and replication of the key 
facets of the phenotype in independent transgenic lines 
harbouring the same construct should be carried out in 
independent laboratories (84), including standardisation of 
expertise of technical personnel and differences in handling 
methods (85). 
 
3.2. Caveats and Pitfalls of Using Mouse Strains 
How close the mouse model replicates the pathology observed 
in a disease may often depend on the design of the model and 
behavioural systems in focus. The choice of a mouse strain is 
crucial, since many strains suitable for genetic manipulation are 
not particularly suitable for behavioural studies (86, 87). Genetic 
background of a mouse strain can be used as a tool in the analysis 
of a mutation (88), and the use of mapping and cloning strategies 
allows the identification of modifier genes existing in different 
mouse strains (89, 90). Noteworthy is that gene targeted 
or transgenic mice are usually initially created on 129 or FVB 
strain backgrounds. The reason for the latter is that the oocytes 
of these strains are large, thus increasing the probability of successful 
injection of the transgene construct. These strains, however, 
are not particularly suitable for behavioural testing (91) and 
it is often necessary to transfer the mutation to a more suitable 
background, usually C57BL/6 strain, by backcrossing for at least 
10 generations. While the strategy largely results in the replacement 
of the donor background with the recipient background, 
the region flanking the selected gene remains likely of donor 
origin. Thus, the genes in this flanking region travel with the 
selected transgene, and when comparing transgenic (or knockout) 
mice with non-transgenic littermates, allelic differences in 
the flanking genes can conceivably influence the traits of interest. 
The problem of genetic background was partially remedied in 
the case of knockout models in which genes are targeted directly 
in C57BL/6-derived embryonic stem (ES) cells (see Knockout 
Mouse Project (KOMP) http://www.komp.org/for further 
information). Many neurodegenerative mouse models, however, 
are still maintained on mixed and segregating genetic backgrounds, 
thus even inbred littermates are not genetically identical. 
Also, one has to bear in mind that many strains, like C3H/HeJ, 
SJL/J, FVB/NJ, MOLF/E, PL/J, SWR/J. BUB/BnJ, CBA/J, 
or NON/LtJ, are not suitable for behavioural testing when visual 
cues are of importance due to the presence of retinal degeneration 
(rd) http://www.jax.org Retinal degeneration (rd) is caused 
by an autosomal recessive mutation resulting in a rapid ageprogressing 
degeneration of rods and cones (92, 93). About 20% 
of all inbred mouse strains carry the rd causing PDE6B gene (94), 
and above listed strains are particularly prone to degeneration 
since they are homozygous for the PDE6B gene. Other strains, 
like A/J, BALB/cByJ, AKR/J, KK/H1J, to mention a few, are 
albino and can be expected to have mild defects in their vision 
(95, 96). Other deficits include age-progressing hearing loss in 
A/J, BALB/cByJ, C57BLKS/J, C57L/J, and C57BR/cdJ (but 
not C57BL/10 J) or other strains (129S1/SvlmJ, BALB/cByJ, 
or I/LnJ) may have partially developed corpus callosum (source, 
http://www.jax.org). In conclusion, taking into account the 
genetic strain background effect on behaviour, the breeding 
scheme of a transgenic line or the generation of multiple transgenic 
lines, the presence of retinal degeneration or other possible 
mutations expressed in homozygous state, the design of the transgenic 
mouse model has to be carefully planned to avoid serious 
confounding variables in most learning tasks which depend on 
visual acuity of animals. The observed pathology in a transgenic 
mouse model may also depend on the choice of the promoter 
used to drive a transgene expression. The most common promoters 
include APP promoter (AD mouse models) (97), brainenriched 
prion protein promoter (98–100), the platelet-derived 
growth factor b-chain (PDGFb) promoter (65) (both PrP and 
PDGF promoters resulting in a transgene expression also outside 
of the CNS), and neuronal specific Thy-1 promoter (101). 
Another problem with transgenic models relates to spontaneous 
genetic changes which may affect the phenotype of a model. Mice 
engineered to overexpress a transgene can potentially with time 
change the number of disease-causing transgene copies, leading 
to possible loss of a phenotype. Without routine checks of a trans-  
gene expression within and between the laboratories, the differences 
in the transgene copy number can prevent replication of the 
results between the laboratories. Awareness of this issue should 
prompt researchers to check periodically the genetic constitution 
of their transgenic stocks. 
 
3.3. Modelling Human Dementia 
Given the disparities between species, it can be challenging to 
draw definitive conclusions about the association of cognitive 
function between humans and transgenic mouse models. In order 
to make appropriate comparisons, tests of memory in rodent 
models of neurodegeneration should target cognitive systems that 
are found and conserved across species, including humans, and 
have a clearly delineated function and a defined neuroanatomy. 
Assessment of spatial navigation and its dependence on the hippocampus 
fulfils the above assumption, since this memory system 
is highly conserved in mammals (102). The neuroanatomical 
structure of hippocampus, together with changes in its synaptic 
plasticity during memory formation (103–110), serves as a welldefined 
model of memory that has been frequently employed in 
studies using rodent species (106, 109–112). Humans with temporal 
lobe damage also have severe impairments in learning and 
memory, including the recall of spatial locations and solving spatial 
maze tasks (113–115), confirming the involvement of the 
hippocampus in spatial memory in humans. Similar findings are 
seen in AD patients, who have significantly increased atrophy of 
the hippocampus (116, 117) and impaired performance in spatial 
navigation tests (118–123). 
 
4. Methods and Experimental Design 
 
4.1. Evaluation of Phenotype 
The evaluation of the phenotype of a new mouse model of 
neurodegeneration should be based on a battery of tests characterising 
the physical and motor development of mice, their 
response to the array of basic stimuli, as well as the characterisation 
of the targeted by the model behavioural system(s). 
The detailed description of each test is beyond the scope of 
this chapter. The reader should consult existing sources, from 
textbooks (124, 125), general articles related to behavioural 
phenotypying (87, 126), specific articles related to analysis of 
strategies (127), memory (128, 129) in a water maze test, or 
methodological procedures related to spatial orientation tests 
(130). More specialised articles describe experimental approaches 
which can enhance learning in strains of mice known as poor 
performers in a specific test (131), or articles comparing performance 
of different species (e.g., rats and mice) in a test 
 (132) and also Chapters 17 and 19 of this volume. Above all, 
the existence of the recently launched Nature Protocols journal 
http://www.nature.com/nprot/index.html which publishes 
detailed experimental protocols, defies any attempt here to provide 
complete guidance to the plethora of behavioural paradigms 
available. Nature Protocols articles not only present theoretical 
background underlying each testing paradigm, detailed procedures, 
examples of collected data, but also suggest type of equipment, 
analyses, including trouble-shooting section. Instead, we 
have provided a list of most frequently used tests accompanied 
with appropriate information which should enable behavioural 
and molecular researchers to use this as a compendium facilitating 
the interpretation of the results found in scientific literature or as 
a starting point in establishing relevant testing paradigms of their 
models. 
 
4.2. Evaluation of Mnemonic Function 
The prevalence of spatial memory tasks in the characterisation 
of mouse models of neurodegeneration (Table 19.1) is justified 
by high evolutionary conservation of spatial memory across 
mammalian species. The main question asked during such characterisation 
relates to the abilities of a mouse genome to cope 
with the presence of an expressed transgene protein. The existence 
of possible effects due to strain genetic background, modifier 
genes, compensatory effects, and/or subtle differences in the 
experimental paradigms, including the strains’ different response 
to handling (133), can yield different, often contradictory results. 
Therefore, a broad characterization of mouse behaviour, including 
both hippocampus-independent memory systems (134–136) 
and other non-cognitive behavioural systems, such as changes in 
agitation and aggression levels (137), locomotor, exploratory, or 
stereotypic activity (138) can be very useful in evaluating transgenic 
mice. The results of such studies not only extend our understanding 
of the effect of these transgene on behaviour but also 
allow us to identify potential confounds in memory tests (139). 
Moreover, studying hippocampus-dependent memory in different 
testing paradigms may sometimes provide interesting additional 
information regarding a particular mouse model. For example, 
the APP Tg2576 mice were tested in T-maze alternation and 
contextual fear conditioning tasks (134). Investigators reported 
a significant impairment in T-maze alternation but, surprisingly, 
they found that the animals were unimpaired in both contextual 
(hippocampus-dependent) and auditory fear conditioning tests 
(hippocampus-independent task). The mice showed attenuated 
contextual discrimination only with a decrease in the salience of 
the context and without changes in tone conditioning discrimination. 
Such detailed validation of the existing mouse models is necessary  
in order to provide a more powerful experimental framework for  
behavioural characterisation of future models and to increase the  
effectiveness of screening of potential therapeutics. A pragmatic  
approach would dictate that robust phenotypes obtained in less  
labile tests (in which data collectionis based on motor or strong  
sensory inputs) would be replicablewithin tolerable margins, while  
more labile phenotypes based onemotional or social behaviours  
may be strongly affected by differencesin laboratory practice (140),  
especially in poorly managed animal colonies. 
 
 
Table 19.1 
Evaluation of cognitive phenotypes of mouse models of neurodegeneration. These 
testing paradigms represent some of the most commonly used tests employed in 
behavioral evaluation of mouse models of neurodegenerative disease (Reprinted 
from (70) with permission) 
 
SHIRPA protocol (147) 
In most cognitive tests, learning rate and memory strength is inferred from measures of 
locomotor behavior, therefore any possible effect of a transgene on motor and/or perceptual 
systems can yield false-positive (impaired learning) results. To this end, a general phenotypic 
assessment of transgenic mice along with non-trangenic littermates must precede specific 
cognitive tests in order to eliminate these possible confounds. SHIRPA protocol provides a 
comprehensive evaluation of mice behavior ranging from the assessment of exploration and 
activity levels to thermal nociception. This battery of simple tests begins with procedures 
most sensitive to physical manipulation, like anxiety tests performed in the open-field or 
elevated plus or zero mazes. Other screens focus on gross phenotyping abnormalities, 
assessment of sensorimotor deficits (rota-rod), holeboard exploratory activity, and thermal 
analgesia. Although application of the full battery can be time consuming and requires a well-
equipped lab, a subset of simple tests can be carried out and is highly recommended 
for initial characterization (126). 
 
MORRIS WATERMAZE (MWM) (148, 149) 
The MWM test has been the most widely used testing paradigm to study hippocampus-
dependent spatial memory in rodent species. Reference memory or place discrimination 
version of MWM requires mice, trained with repeated trials over several days, to use external 
visual cues around the testing room to search for the hidden (barely submerged) escape 
platform in the water maze. Spatial navigation encompasses the development of different 
search strategies with spatial strategy (reflected by a direct swim to a platform) taking place 
at the end of this complex learning process (127, 150). The main dependent variable 
reflecting learning acquisition is escape latency - the time it takes a mouse to find a platform, 
or search path, which is less biased by the differences in swim speed. Memory bias is 
evaluated in trials where a mouse searches a pool where the hidden platform has been 
removed. Spatial learning is reflected by decreased escape latency or search path, while 
spatial memory by increased search in areas or quadrants of the pool containing a platform 
during training. An annulus-crossing index (a number of swimming over former platform 
location adjusted for swims in other 3 quadrants of a pool (127, 151, 152)) represents an 
alternative, more stringent measure of memory bias. In cases when more than one probe 
trial is carried out during training, a mean probe score (the mean percent of time spent in 
target quadrant during all probes (153)) can be used as a reliable memory evaluation index. 
Correspondingly, learning impairment is reflected by longer escape latency or search path 
during training, and memory impairment by displaced or random search, which is reflected by 
about 25% of time, spent in each of quadrant of the pool during a probe trial. To address 
episodic-like memory in mice, a more complex version of the MWM test was developed 
(154). In this test, numerous locations of the platform were used and the number of new 
locations learned during the whole training reflects learning capacity of an individual mouse. 
In a cued or visible platform version of the MWM test a platform location is marked by a 
visible cue that mice associate with an escape from water. This version of the test is often 
implemented as a control for normal visual acuity, an unimpaired learning of simple 
association between a proximal cue and an escape platform, or as demonstration of a 
comparable swim speed between studied genotypes. These controls should be used with 
caution, however, because in contrast to rats, some strains of mice with hippocampal lesions 
often show also partial impairment in the cue navigation task (155). 
  
OBJECT RECOGNITION (OR) (156, 157) 
This test exploits a natural tendency of rodents to explore novel objects and to show an 
exploratory preference for replaced or displaced objects. The dependence of object 
recognition memory on the hippocampus is related to the protocol of a test. Short delays 
between initial exploration phase and a memory test make OR test independent from the 
hippocampus (136), however, when longer delays (hours) are implemented, OR memory 
depends on hippocampus function (158, 159). Object memory impairment is demonstrated 
when an animal shows no preference in exploration (close proximity, nose contact) of a new 
or displaced object. 
 
FEAR CONDITIONING (FC) (160, 161) 
The FC paradigm which is an example of classical Pavlovian associative learning and 
involves an association of a neutral tone (conditioned stimulus, CS) paired with a brief 
electric foot-shock (unconditional stimulus, US) delivered in a novel context. Mice trained in 
that manner develop a fear response (conditioned response, CR), expressed as defensive or 
anti-predatory behavior in a form of freezing (complete cessation of movement) which 
coincides with autonomic and endocrine response (increased heart beat rate and blood 
pressure), and sensory alteration (analgesia, potentiated startle). The paradigm may involve 
two types of conditioning that can be performed simultaneously or independently during a 
training phase: contextual (CFC), when an animal develops an association between shock 
and training context (conditioning chamber), and tone fear conditioning when shock (US) is 
associated with a neutral tone (CS). The tone conditioning is performed either as delay 
conditioning paradigm when there is a temporal overlap between CS and US (a foot-shock 
is delivered within the last 1–2 s of tone duration), or more demanding trace fear conditioning 
which requires the association of a CS with an US across an interval of time known as trace 
interval (a foot-shock [US] is delivered after the tone [CS] is turned off). The time between 
CS and US can vary and an additional temporal processing is required because CS and US 
are separated therefore an animal has to retain a trace of CS across this time interval in 
order to associate it with the US. While delay tone conditioning is hippocampus independent 
but requires intact amygdale (162, 163), the trace and contextual fear conditioning are 
sensitive to hippocampal lesions (161, 164). The sensitivity of the mice to foot-shock can be 
established empirically recording the current thresholds that elicit specific response like 
flinch, jump (165). The lowest current eliciting learning (for mice a current of 0.35–0.4 mA is 
appropriate) should be used. Impairment in FC is evaluated during test phase on the 
following day after training, and is reflected by reduced freezing time when an animal is 
placed in familiar chamber (context conditioning) or when the animal is exposed to a 
conditioned tone in a new environment. 
 
CONDITIONED TASTE AVERSION (CTA) (166–168) 
CTA is a special form of classical Pavlovian conditioning, representing an adaptive 
specialization which defends an organism against repeated ingestion of toxic foods (166–
169). CTA is well conserved in many different species including humans (169, 170). When 
acquiring a CTA response, an animal learns to associate the specific taste of a novel food, 
usually a saccharine solution (conditioned stimulus, CS) with experimentally induced through 
i.p. injection of lithium chloride after saccharine intake (unconditioned stimulus, US), nausea. 
Because of one trial pairing between CS and US, a long-lasting avoidance of food with this 
specific taste develops. The brain areas implicated in the CTA include the agranular insular 
cortex, the parvicellular thalamic ventral posteromedial nucleus, and the parabriachial 
nucleus of the pons, which are part of the gustatory pathway (171, 172) and the amydgala 
(173, 174). Impairment in CTA is reflected by increased saccharine intake as compared to 
control mice in choice tests (usually two bottles test, one containing water, one saccharine). 
 
4.3. Experimental Design 
The purpose of doing experiments is to distinguish between alternative 
hypotheses or explanations. However, even a perfectly 
designed experiment might lack sufficient power, if sample sizes 
of animals in experimental groups are small. Since it is often not 
known what effect on behaviour a mutation exerts, it is advisable 
to properly characterize a non-transgenic or wild-type control 
mice, thus establishing a yardstick for robust characterization of 
the phenotype in question, avoiding floor or ceiling effects in the 
data recording which can cause a skewed data distribution. Larger 
sample sizes are desirable (n = 8–12, or more (141) depending 
how robust a focal behaviour is), but attention has to be paid to 
ensure that the mice are not tested too long during the day, which 
may result in their fatigue or may span over different phases of 
the circadian cycle. Also, one has to be aware that a change in 
behaviour of mice may sometimes be caused not by the experimental 
treatment, but merely by the handling or attention paid 
to them by the experimenter. The effect, known in psychology as 
the Hawthorne effect (142), is often a cause of differences between 
the obtained results in various laboratories (85). A common error, 
which occurs less often in behavioural research but crops up frequently 
in physiological experiments, refers to treating repeated 
data points coming from the same subjects as independent from 
each other measures. This approach, called pooling fallacy (143), 
leads to an inappropriate increase in the sample size of mixed, 
dependent, and independent data points, thus violating many 
assumptions of experimental design and parametric data analysis. 
Problems with independence of data may arise in less obvious 
situations, when the obtained data correlate closely between 
mice coming from the same litter or between mice housed in the 
same cage. These litter- or cage-effects can be the result of, for 
example, differential maternal care, highly variable housing conditions 
(mice in cages placed at the bottom of a rack in a densely 
populated with racks rooms are kept in constant semi-darkness), 
singly housed animals are known to perform worse in learning and 
memory tasks, etc., and can introduce confounding factors often 
impossible to overcome due to the small number available and 
often difficult to derive mutant mice. Awareness of these issues, 
however, may help during the inspection and first steps in the 
interpretation of the raw data. If the data generated by mice from 
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the same litter or cage are on one spectrum of the distribution, 
one should consider the replication of the experiment using more 
careful and balanced assignment of mice to experimental groups. 
 
4.4. Data Analysis Most experiments, especially those evaluating learning and memory 
involve repeated tests or training sessions. Results are usually 
presented in blocks of training trials or days. Plotting data in 
that fashion usually reflects adequately the learning process, but 
blocking data over repeated trials reduces variance and may result 
in some unusual patterns of behaviour escaping attention. It is 
advisable, therefore to inspect the raw data, especially the data 
generated from first training trials to check if mutant mice are free 
from subtle motor or sensory deficits. It can be assumed that control 
and mutant mice, which are well habituated to handling and 
lab conditions but na¨ıve to a particular behavioural test, should 
show comparable performance during first training trial(s). Any 
cognitive impairment, if not confounded by compromised locomotor 
or sensory deficiency, should become apparent as training 
progresses, but should not be present at the beginning of 
training, unless of course the severity of cognitive decline impairs 
the interaction of an animal with the surrounding environment. 
Data are generally analyzed by analysis of variance (ANOVA), 
with genotype and/or treatment as between subject factors and 
training days and/or trials as within-subject factor(s). One issue 
to remember is that the data must meet the criteria of parametric 
statistics and in the case of repeated measure or within-subject factor, 
an assumption of compound symmetry must be met in order 
to avoid bias in the interpretation of the results of a test involving 
within-subject factor. The assumption of compound symmetry 
refers to a pattern of constant variances on the diagonal and 
constant covariances off the diagonal in the variance–covariance 
matrix. In practice this means that the correlations within the 
matrix of the repeated factor (days or trials) have to be the same 
at all distances between measurements. This assumption, however, 
is hardly met in the analysis of learning data, since as animals 
learn over time and improve their performance in a task, 
thus the variance decreases as learning progresses. A departure 
from the assumption of compound symmetry is usually evaluated 
by slightly the more stringent sphericity test (Mauchly sphericity 
test, SPSS GLM (Statistical Package for Social Sciences, SPSS Inc. 
Chicago)), and in cases of severe departures, degrees of freedom 
should be adjusted either by Greenhouse–Geisser ε-correction 
(tends to underestimate, especially when ε is close to 1) or by 
Huynh–Feldt estimator (which tends to overestimate ε) to avoid 
false-positive results (144). 
 
4.5. Animal Facility and Behavioural Tests 
Replication of the results are at the core of the falsification process 
of hypotheses or theories (145). However, even the best guidance  
or step-by-step description of procedures and methods pertaining  
to a specific testing paradigm may often yield unpredictable and  
different results between laboratories, despite very careful execution  
by experienced in the field researchers (84). 
Therefore, in this section we would like to alert readers to some 
potential problems and issues which may affect the execution of 
behavioural experiments and resulting data. The list of presented 
issues, by no means exhaustive, includes problems which are often 
not formally documented, or issues which are considered trivial or 
too obvious to mention in many the Material and Methods sections 
but are highly relevant. 
The characterisation of behavioural phenotypes starts with 
housing conditions in the animal facility. Animal rooms located 
in the vicinity of noisy, heavy traffic areas, like cage washing areas, 
are less desirable and in some cases may even lower the breeding 
rate, induce cannibalism, and increase hyper-reactivity in animals. 
The housing conditions, including the number of mice in 
a cage (not more than four mice over extended period), having 
minimum and consistent level of enrichment in a form of 
pressed cotton nesting material (nestlets), mouse huts or igloos, 
or pup tents (source http://www.bio-serv.com/) can significantly 
improve breeding and reduce anxiety of animals. Housing 
mice singly in cages is not recommended due to heightened 
rate of developing stereotyping behaviour, obesity, and decreased 
performance in learning ability. When breeding transgenic lines, 
it is not uncommon that the newly born transgenic pups tend 
to be smaller then their non-transgenic littermates (for example 
in the case of APP TgCRND8 mice, personal observation). 
Supplementing lactating females and their pups, especially at the 
pups age when they start to consume solid food (14–15 days of 
age), with easily available and more palatable moister powdered 
mouse Purina chow in a Petri dish, facilitates pups’ growth and 
can reduce the weight difference between transgenic TgCRND8 
and their non-Tg littermates (unpublished data). The distance 
of the housing room to the behavioural testing room(s) is relevant 
and the transportation of mice between the two locations 
can be stressful, therefore adding appropriate time for acclimation 
to new testing conditions should be done. Last but not least, husbandry 
practices including care and feeding of animals, cleaning 
of equipment, physical surroundings, and routine checks of the 
stock health by experienced, well-trained, and well-managed facility 
staff guarantee good health, growth, reproduction, survival 
of mice. Personnel with poor management and/or inexperience 
in mouse handling and husbandry may adversely affect animal 
stress level and behaviour. Excessive noise produced during cage 
changing (for example changing cages under a hood and putting 
or stacking metal cage lids on the metal surface produces 
extremely noisy conditions, including high levels of ultrasounds 
which mice are sensitive to), undetected leaking water bottles or 
wet cleaning equipment (mops and buckets) left in animal rooms 
produce impossible to pin point confounding variables all of 
which increase stress and anxiety levels of mice, consequently negatively 
and variably affecting their performance in the behavioural 
tests. 
As an example, in Fig. 19.1 we provide the results of training 
two cohorts of same-age C3B6 mice (mixed genetic background 
of C3 (C3H) and B6 (C57BL/6)) in the spatial reference 
memory version of a water maze test, in two different animal 
facilities. Both cohorts were trained by the same laboratory assistant, 
highly experienced with the behavioural procedure, mouse 
husbandry, and certified in laboratory animal medicine. Mice in 
animal facility A were maintained in a quiet room and highly 
qualified and well-managed personnel provided high quality husbandry 
care. The environment in colony B was more stressful and 
mice were exposed to noisy conditions. The comparison of mice 
performance between colonies (main between-subject factor) and 
the analysis of their learning (days as repeated measure or withinsubject 
factor) revealed no significant difference in the average 
performance between the colonies (F(1,23) = 1.2, NS), but it 
also revealed a significant interaction between the colony conditions 
and learning rate of mice (F(4,92) = 4.2, p < 0.01, colony 
by training days interaction). Mice in colony A showed a significant 
learning through a rapid improvement in their search for a 
hidden escape platform over days (Fig. 19.1, p < 0.001 – simple 
effects ANOVA with days as a repeated measure), whereas the 
mice in colony B, however, did not show any signs of improvement 
over training period (Fig. 19.1). 
 
 
Fig. 19.1. Learning acquisition in the spatial reference memory version of a water maze test 
of mixed background C3B6 mice in two different animal colonies. Mice in the colony A were 
kept in a quiet room with appropriate for behavioral experiments husbandry practices, while 
the colony B had increased noise level and sub-optimal for behavioral studies conditions. 
The mice trained in the colony A showed a significant improvement in finding a hidden 
platform location during training (their search path was on average about 5 m shorter at the 
end of training as compared to at the beginning of training). On the other hand, the mice in 
colony B showed no improvement (the rate of improvement between day 1 and day 5 was 
about 1 m). See text for further details. 
 
5. Conclusions 
The main goal of the generation of animal models of human diseases 
is to better understand their underlying pathology, which 
should lead to the discovery and tests of potential therapeutics. 
In our review we focused on neurodegenerative diseases which 
present a complex, age-progressing dementia with rapidly progressing 
neuronal death. It might be unrealistic to think that the 
full complexity of human brain disorder can be modelled in a 
mouse using a crude, single genetic modification. However, as 
we tried to outline in this chapter, the interpretation of the results 
coming from mouse models of neurodegeneration should not 
follow ―one gene – one disease‖ paradigm. At present, none of the 
existing mouse models of tauopathy fully replicate the characteristics 
of the modelled disease. Using these mouse models to study 
well-conserved signalling pathways in vivo may be better warranted 
than replicating fully the complexity of dementia. Genetically 
modified mouse models are integral part of modern drug 
discovery, but the interpretation of the obtained results must be 
careful and carried out within constraints of a model and mouse 
biology. The intensive screens of many compounds would require 
systematic, well-controlled, standardized phenotyping approach 
which is presented by Sacca and colleagues in Chapter 3 of this 
volume. The initial characterisation of new models or detailed 
characterisation of specific aspects of existing models should be 
based on careful experimental design, including larger number 
of mice in completely randomized experimental designs in animal 
facilities which promote maximal expression of mouse natural 
behaviour. Rigor of the experimental design will ensure replicability 
of the results across the labs and between different models. 
Even seemingly good and robust models of a human disease 
can yield many false-positive results due to differences in 
methodology or less rigorously carried out experiments (146). 
Our intention is to highlight important aspects of experimental 
design which are not always identified a priori and which may 
often generate confounding factors seriously biasing obtained 
data. We argue that our success in the endeavour of modelling 
human cognitive impairment may often depend on how well we 
understand the behaviour of a mouse. Detailed analysis of the 
potential and limitation of a model and the interpretation of the 
results within the framework of mouse biology should improve 
considerably detailed evaluation of potential therapeutics. Testing 
a specific hypothesis, negative results should be as valuable 
as positive ones and should be made available to the scientific 
community. 
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